Management and outcome of locally advanced oral squamous cell carcinoma.

National Journal of Maxillofacial Surgery Pub Date : 2023-05-01 Epub Date: 2023-07-13 DOI:10.4103/njms.njms_125_22
Rathindra N Bera, Sapna Tandon, Akhilesh K Singh, Fargol M A Boojar, Gaurav Jaiswal, Shraddha Borse, Uma S Pal, Naresh K Sharma
{"title":"Management and outcome of locally advanced oral squamous cell carcinoma.","authors":"Rathindra N Bera,&nbsp;Sapna Tandon,&nbsp;Akhilesh K Singh,&nbsp;Fargol M A Boojar,&nbsp;Gaurav Jaiswal,&nbsp;Shraddha Borse,&nbsp;Uma S Pal,&nbsp;Naresh K Sharma","doi":"10.4103/njms.njms_125_22","DOIUrl":null,"url":null,"abstract":"<p><p>Management of locally advanced OSCC is multimodal. No single therapy has been proved to be efficacious. However there is a trend towards surgical intervention in operable disease. In this review we appraise the various therapies used for the management of locally advanced OSCC. We review the literature with regards to the various treatment options for locally advanced OSCC. We categorically divided the manuscript into resectable, unresectable and technically unresectable disease. Surgery is the ideal treatment modality for resectable disease. For unresectable disease concurrent chemoradiation appears to improve survival compared to radiotherapy alone. Induction therapy might downstage tumors in the unresectable category. Targeted and Immunotherapy is reserved for recurrent, metastatic or platinum refractory OSCC. Management of locally advanced OSCC is multimodal with surgery playing the primary role. In the event where the tumor is in operable concurrent chemoradiotherapy is regarded as the best treatment modality. Induction chemotherapy currently cannot be recommended for resectable or even unresectable oral squamous cell carcinomas. However for technically unresectable disease it might play a role in improving respectability but it depends on the response of the tumor. Targeted therapy and immunotherapy is currently used for recurrent, metastatic and/or platinum refractory Head and Neck cancers. Currently it is not recommended for initial management of locally advanced disease.</p>","PeriodicalId":18827,"journal":{"name":"National Journal of Maxillofacial Surgery","volume":"14 2","pages":"185-189"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/5c/NJMS-14-185.PMC10474551.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"National Journal of Maxillofacial Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/njms.njms_125_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/13 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Management of locally advanced OSCC is multimodal. No single therapy has been proved to be efficacious. However there is a trend towards surgical intervention in operable disease. In this review we appraise the various therapies used for the management of locally advanced OSCC. We review the literature with regards to the various treatment options for locally advanced OSCC. We categorically divided the manuscript into resectable, unresectable and technically unresectable disease. Surgery is the ideal treatment modality for resectable disease. For unresectable disease concurrent chemoradiation appears to improve survival compared to radiotherapy alone. Induction therapy might downstage tumors in the unresectable category. Targeted and Immunotherapy is reserved for recurrent, metastatic or platinum refractory OSCC. Management of locally advanced OSCC is multimodal with surgery playing the primary role. In the event where the tumor is in operable concurrent chemoradiotherapy is regarded as the best treatment modality. Induction chemotherapy currently cannot be recommended for resectable or even unresectable oral squamous cell carcinomas. However for technically unresectable disease it might play a role in improving respectability but it depends on the response of the tumor. Targeted therapy and immunotherapy is currently used for recurrent, metastatic and/or platinum refractory Head and Neck cancers. Currently it is not recommended for initial management of locally advanced disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
局部晚期口腔鳞状细胞癌的治疗和转归。
本地高级OSCC的管理是多模式的。没有一种单一的治疗方法被证明是有效的。然而,对可手术的疾病进行外科干预是一种趋势。在这篇综述中,我们评估了用于治疗局部晚期OSCC的各种疗法。我们回顾了关于局部晚期OSCC的各种治疗方案的文献。我们将手稿明确地分为可切除、不可切除和技术上不可切除的疾病。手术是可切除疾病的理想治疗方式。对于不可切除的疾病,与单独放疗相比,同时放化疗似乎可以提高生存率。诱导治疗可能降低不可切除肿瘤的分期。靶向和免疫治疗保留用于复发性、转移性或铂类难治性OSCC。局部晚期OSCC的管理是多模式的,手术起主要作用。在肿瘤处于可手术状态的情况下,同步放化疗被视为最佳治疗方式。诱导化疗目前不能推荐用于可切除甚至不可切除的口腔鳞状细胞癌。然而,对于技术上不可切除的疾病,它可能在提高体面方面发挥作用,但这取决于肿瘤的反应。靶向治疗和免疫疗法目前用于复发性、转移性和/或铂类难治性头颈癌。目前不建议对局部晚期疾病进行初步治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Soft skills for personal development of the surgeon for improved outcomes for patient and surgeon. Oral rhabdomyosarcoma of mandibular region: A case report. Evaluation of efficacy of simvastatin in bone regeneration following local application in third molar extraction socket: A randomized control trial. Comparative evaluation of implant stability and crestal bone level between tapered and cylindrical implants in the posterior regions of the mandible: A prospective, randomized, split-mouth clinical trial. Comparative and clinical evaluation between piezoelectric and conventional rotary techniques for mandibular impacted third molar extraction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1